The chromogranin A-derived peptides catestatin and vasostatin in dogs with myxomatous mitral valve disease

Table 1 Dog characteristics, clinical and echocardiographic data in 67 dogs grouped by severity of myxomatous mitral valve disease (MMVD)

Group	Healthy	Mild	Moderate	Severe
Number	20	23	8	16
Sex (female/male)	14/6	15/8	5/3	4/12
Age (years)	4.9 (2.8–6.4)^a	7.2 (6.2–10)^b	9.1 (7.0–10)^b	9.2 (8.7–11)^b
Body Weight (kg)	8.8 (7.0–10.1)^a	9.6 (8.0–10.6)^a	8.9 (7.6–10)^a	10 (7.7–12)^a
HR (bpm)	100 (93–111)^a	100 (92–112)^a	100 (100–120)^ab	120 (100–150)^bc
SBP (mmHg)	134 (119–138)^ab	139 (132–152)^a	139 (127–153)^ab	123 (116–134)^b
DBP (mmHg)	75 (65–80)^ab	78 (70–86)^a	75 (72–80)^ab	68 (64–75)^b
LA/Ao	1.2 (1.1–1.2)^a	1.3 (1.2–1.4)^b	1.6 (1.5–1.6)^c	2.1 (2.0–2.6)^d
LVIDd (cm)	3.0 (2.7–3.4)^a	3.4 (3.1–3.7)^ab	3.5 (3.4–3.9)^b	4.4 (4.1–4.8)^c
LVIDd_inc (%)	4.0 (− 2.4 to 15)^a	14 (4.5–24)^ab	24 (16–38)^b	45 (41–59)^c
LVIDs (cm)	2.1 (1.8–2.5)^a	2.3 (2.1–2.7)^a	2.3 (2.2–2.7)^ab	2.7 (2.5–3.2)^bc
LVIDs_inc (%)	8.4 (− 0.4 to 30)^a	21 (12–41)^a	22 (17–42)^ab	43 (25–58)^bc
FS (%)	31 (27–34)^a	29 (25–34)^a	35 (31–37)^ab	37 (31–41)^bc
Catestatin (nmol/L)	1.2 (1.0–1.3)^a	1.1 (1.0–1.2)^a	1.1 (0.9–1.3)^a	1.1 (0.9–1.2)^a
Vasostatin (nmol/L)	0.23 (0.15–0.33)^a	0.18 (0.13–0.28)^a	0.22 (0.14–0.44)^a	0.16 (0.11–0.30)^a
NT-proBNP (pmol/L)	549 (375–800)^a	473 (386–690)^a	529 (420–836)^a	3000 (2129–3000)^b

Heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), echocardiographic data; ratio of left atrium to aortic root (LA/Ao), percentage increase in end-diastolic left ventricular internal dimension, (LVIDd_inc) and end-systolic left ventricular internal dimension (LVIDs_inc), fractional shortening (FS), N-terminal-pro B-type natriuretic peptide (NT-proBNP). Values are reported as median and interquartile ranges (IQR). Within each row, values with the same superscript letter did not differ significantly (P > 0.008)

ISSN: 1751-0147